Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alnylam Pharmaceuticals (ALNY)
NASDAQ:ALNY
Alnylam Pharma (ALNY) Stock Price & Analysis
1,111 Followers
ALNY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$141.98 - $263.73
Previous Close$237.83
Volume878.60K
Average Volume (3M)1.01M
Market Cap
$30.08B
Enterprise Value$28.95B
Total Cash (Recent Filing)$2.44B
Total Debt (Recent Filing)$1.31B
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Aug 01, 2024EPS Estimate
-$1.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.68
Shares Outstanding126,491,778
10 Day Avg. Volume787,866
30 Day Avg. Volume1,008,666
Standard Deviation0.12
R-Squared0.02
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-94.99
Price to Sales (P/S)47.67
Price to Cash Flow (P/CF)-175.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue15.95
Enterprise Value/Gross Profit19.07
Enterprise Value/Ebitda-113.16
Forecast
1Y Price Target
$267.58Price Target Upside12.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
Alnylam Pharma News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsHighly positive HELIOS-B topline results for Amvuttra in ATTR-CM with statistically significant improvements across all key secondary endpoints.
Market ShareRecent survey suggested a 53% market share two years after approval if HELIOS-B was successful.
Product SalesIn 2023, direct product sales by Alnylam of its 4 RNAi therapeutics crossed the billion dollar mark ($1.24 bn, +39%).
Bears Say
Market And Competitive DynamicsUnclear rationale for a drug 2x the price with 80% of patients untreated and tafamidis genericization looming.
Regulatory And Clinical RisksRisks include clinical development risk tied to hepatic and extrahepatic pipeline assets, competitor risk in relevant therapeutic areas, and other risks including commercialization and pricing risk.
Stock ValuationThe ATTR-CM opportunity and reasonable platform credit are more or less priced in to the stock at these levels.
---
Ownership Overview
16.47% Insiders
46.15% Mutual Funds
15.86% Other Institutional Investors
21.52% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ALNY FAQ
What was Alnylam Pharmaceuticals’s price range in the past 12 months?
Alnylam Pharmaceuticals lowest stock price was $141.97 and its highest was $263.73 in the past 12 months.
What is Alnylam Pharmaceuticals’s market cap?
Currently, no data Available
When is Alnylam Pharmaceuticals’s upcoming earnings report date?
Alnylam Pharmaceuticals’s upcoming earnings report date is Aug 01, 2024 which is in 10 days.
How were Alnylam Pharmaceuticals’s earnings last quarter?
Alnylam Pharmaceuticals released its earnings results on May 02, 2024. The company reported -$0.52 earnings per share for the quarter, beating the consensus estimate of -$1.116 by $0.596.
Is Alnylam Pharmaceuticals overvalued?
According to Wall Street analysts Alnylam Pharmaceuticals’s price is currently Undervalued.
Does Alnylam Pharmaceuticals pay dividends?
Alnylam Pharmaceuticals does not currently pay dividends.
What is Alnylam Pharmaceuticals’s EPS estimate?
Alnylam Pharmaceuticals’s EPS estimate is -$1.05.
How many shares outstanding does Alnylam Pharmaceuticals have?
Alnylam Pharmaceuticals has 126,491,776 shares outstanding.
What happened to Alnylam Pharmaceuticals’s price movement after its last earnings report?
Alnylam Pharmaceuticals reported an EPS of -$0.52 in its last earnings report, beating expectations of -$1.116. Following the earnings report the stock price went up 0.233%.
Which hedge fund is a major shareholder of Alnylam Pharmaceuticals?
Among the largest hedge funds holding Alnylam Pharmaceuticals’s share is Dodge & Cox. It holds Alnylam Pharmaceuticals’s shares valued at 570M.
---
Alnylam Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$267.58 (12.51% Upside)
$267.58 (12.51% Upside)
Blogger Sentiment
Bullish
ALNY Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 41.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 21.1%
Last 30 Days ▲ 21.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.83%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
12.75%
Trailing 12-Months
Company Description
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
---
ALNY Company Deck
---
ALNY Earnings Call
Q1 2024
0:00 / 0:00
---
ALNY Revenue Breakdown
67.90% Net product revenues
29.87% Net revenues from collaborations
2.22% Royalty revenue
---
ALNY Stock 12 Month Forecast
Average Price Target
$267.58
▲(12.51% Upside)
Technical Analysis
Best Analysts Covering ALNY
1 Year
1 Year Success Rate
16/20 ratings generated profit
1 Year Average Return
+25.77%
reiterated a buy rating 4 months ago
Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +25.77% per trade.
---